AbbVie Assumes Two Interchangeable Humira Biosimilars In 2023

Up To Nine Adalimumab Biosimilars to Launch In Key Year

 
• By Dean Rudge
  
Billion_Dollar
Humira was a $15bn opportunity in the US in 2019 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products